NASDAQ:CRIS - Curis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.90 +0.01 (+0.53 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$1.88
Today's Range$1.87 - $1.94
52-Week Range$1.57 - $11.35
Volume140,000 shs
Average Volume424,548 shs
Market Capitalization$62.94 million
P/E Ratio-1.06
Dividend YieldN/A
Beta1.28
Curis logoCuris, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

Receive CRIS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CRIS
CUSIP23126910
Phone617-503-6500

Debt

Debt-to-Equity Ratio2.24
Current Ratio3.60
Quick Ratio3.60

Price-To-Earnings

Trailing P/E Ratio-1.06
Forward P/E Ratio-1.14
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.90 million
Price / Sales6.36
Cash FlowN/A
Price / CashN/A
Book Value$0.73 per share
Price / Book2.60

Profitability

EPS (Most Recent Fiscal Year)($1.80)
Net Income$-53,310,000.00
Net Margins-472.13%
Return on Equity-247.46%
Return on Assets-68.71%

Miscellaneous

Employees55
Outstanding Shares33,130,000
Market Cap$62.94

The Truth About Cryptocurrencies

Curis (NASDAQ:CRIS) Frequently Asked Questions

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

When did Curis' stock split? How did Curis' stock split work?

Curis shares reverse split before market open on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) issued its quarterly earnings data on Thursday, May, 3rd. The biotechnology company reported ($0.35) EPS for the quarter, topping the Zacks' consensus estimate of ($0.45) by $0.10. The biotechnology company had revenue of $2.47 million for the quarter, compared to analyst estimates of $2.30 million. Curis had a negative return on equity of 247.46% and a negative net margin of 472.13%. View Curis' Earnings History.

When is Curis' next earnings date?

Curis is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Curis.

What price target have analysts set for CRIS?

2 brokers have issued twelve-month price objectives for Curis' stock. Their forecasts range from $30.00 to $35.00. On average, they expect Curis' share price to reach $32.50 in the next year. This suggests a possible upside of 1,610.5% from the stock's current price. View Analyst Ratings for Curis.

What is the consensus analysts' recommendation for Curis?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Curis' key competitors?

Who are Curis' key executives?

Curis' management team includes the folowing people:
  • Dr. Ali Fattaey, CEO, Pres & Director (Age 53)
  • Mr. James E. Dentzer, COO, CFO & Chief Admin. Officer (Age 51)
  • Dr. David Tuck, Sr. VP & Chief Medical Officer (Age 66)
  • Mr. Mark W. Noel, VP of Technology Management & Intellectual Property (Age 59)
  • Dr. Minji Kim Ph.D., MBA, VP of Corp. & Bus. Devel.

Has Curis been receiving favorable news coverage?

News headlines about CRIS stock have trended somewhat positive on Monday, Accern Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Curis earned a media sentiment score of 0.10 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.85 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Curis?

Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Curis' stock price today?

One share of CRIS stock can currently be purchased for approximately $1.90.

How big of a company is Curis?

Curis has a market capitalization of $62.94 million and generates $9.90 million in revenue each year. The biotechnology company earns $-53,310,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Curis employs 55 workers across the globe.

How can I contact Curis?

Curis' mailing address is 4 MAGUIRE ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]


MarketBeat Community Rating for Curis (NASDAQ CRIS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  359 (Vote Outperform)
Underperform Votes:  279 (Vote Underperform)
Total Votes:  638
MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe CRIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRIS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.